๐ ๐ผ๐ฑ๐ฒ๐ฟ๐ป๐ฎ ๐๐ถ๐ป๐ $๐ญ๐ณ๐ฒ๐ ๐๐๐ฅ๐๐ ๐ฎ๐๐ฎ๐ฟ๐ฑ ๐๐ผ ๐ณ๐ถ๐ป๐ฎ๐ป๐ฐ๐ฒ ๐ฏ๐ถ๐ฟ๐ฑ ๐ณ๐น๐ ๐๐ผ๐ฟ๐ธ Moderna received a significant boost from the federal government, snagging a $176 million contract to help advance a bird flu vaccine. The award, which was โฆ https://lnkd.in/ddasMenm
Luminary Groupโs Post
More Relevant Posts
-
๐๐๐บ๐ถ๐ป๐ฎ๐ฟ๐ ๐๐ฟ๐ผ๐๐ฝ, ๐๐น๐ผ๐ฏ๐ฎ๐น ๐๐ถ๐ณ๐ฒ ๐ฆ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ๐ ๐๐ผ๐ป๐๐๐น๐๐ฎ๐ป๐ฐ๐ #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
Luminary Group, Global Life Sciences Consultancy - Real World Evidence, AI, eClinical & Consulting
To view or add a comment, sign in
-
๐๐น๐ฎ๐ด๐๐ต๐ถ๐ฝ ๐ฟ๐ฒ๐ฒ๐น๐ ๐ถ๐ป $๐ฏ.๐ฒ๐ ๐๐ผ ๐ฐ๐ฟ๐ฒ๐ฎ๐๐ฒ ๐ฎ๐ฑ ๐ป๐ฒ๐ ๐ฐ๐ผ๐บ๐ฝ๐ฎ๐ป๐ถ๐ฒ๐ Flagship Pioneering,the 25-year-old life sciences incubator and investor, has reeled in $3.6 billion to build another 25 or so companies, it. Noubar Afeyan https://lnkd.in/dT7Sy5rt
Flagship raises $3.6B for 25 new startups
https://endpts.com
To view or add a comment, sign in
-
๐๐ฟ๐ฐ๐๐๐ถ๐ ๐๐ฎ๐ฐ๐ธ๐ ๐ผ๐ป ๐ฎ๐๐ผ๐ฝ๐ถ๐ฐ ๐ฑ๐ฒ๐ฟ๐บ๐ฎ๐๐ถ๐๐ถ๐ ๐ฎ๐ฝ๐ฝ๐ฟ๐ผ๐๐ฎ๐น ๐ณ๐ผ๐ฟ ๐ญ๐ผ๐ฟ๐๐๐ฒ ๐ฐ๐ฟ๐ฒ๐ฎ๐บ The FDAQRC approved Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) skin treatment Zoryve to treat mild to moderate atopic dermatitis in adults and some children, theโฆFrank Watanabe https://lnkd.in/dFatqhVQ
Arcutis tacks on atopic dermatitis approval for Zoryve cream
https://endpts.com
To view or add a comment, sign in
-
๐ฉ๐ ๐ณ๐ถ๐ฟ๐บ ๐ฒ๐บ๐ฒ๐ฟ๐ด๐ฒ๐ ๐๐ผ ๐ฏ๐ผ๐ผ๐๐ ๐๐๐๐๐ฟ๐ถ๐ฎ๐ป ๐ฏ๐ถ๐ผ๐๐ฒ๐ฐ๐ต ๐๐ฐ๐ฒ๐ป๐ฒ ๐๐ต๐ฎ๐โ๐ โ๐ฟ๐ฒ๐ฎ๐ฑ๐ ๐๐ผ ๐ฏ๐ฟ๐ฒ๐ฎ๐ธ ๐ผ๐๐โ When Christopher Trummer tried raising money for his molecular glue degrader startup, he struggled to find VC support in his native Austria โฆVenga Ventures, Florian Schuster https://lnkd.in/dj78yAWT
VC firm emerges to boost Austrian biotech scene thatโs โready to break outโ
https://endpts.com
To view or add a comment, sign in
-
๐ช๐ต๐ฒ๐ป ๐ฐ๐ฎ๐ป ๐ฝ๐ต๐ฎ๐ฟ๐บ๐ฎ ๐ฐ๐ผ๐บ๐ฝ๐ฎ๐ป๐ถ๐ฒ๐ ๐ฐ๐ผ๐ฟ๐ฟ๐ฒ๐ฐ๐ ๐ผ๐ป๐น๐ถ๐ป๐ฒ ๐บ๐ถ๐๐ถ๐ป๐ณ๐ผ๐ฟ๐บ๐ฎ๐๐ถ๐ผ๐ป? ๐๐๐ ๐ฒ๐ ๐ฝ๐น๐ฎ๐ถ๐ป๐ The FDAQRC on Monday laid out its latest expectations for how pharma companies can correct misinformation spreading online about their medical products. The draft guidance โฆRobert Califf https://lnkd.in/dCXRXEzM
When can pharma companies correct online misinformation? FDA explains
https://endpts.com
To view or add a comment, sign in
-
๐๐ฒ๐ฟ๐บ๐ฎ๐ป ๐ฎ๐ป๐๐ถ๐ฏ๐ผ๐ฑ๐ ๐ฐ๐ผ๐บ๐ฝ๐ฎ๐ป๐ ๐๐ฒ๐ฐ๐๐ฟ๐ฒ๐ โฌ๐ฒ๐ฏ๐ ๐ณ๐ผ๐ฟ ๐ฎ๐๐๐ผ๐ถ๐บ๐บ๐๐ป๐ฒ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ ๐ฝ๐ฟ๐ผ๐ด๐ฟ๐ฎ๐บ SciRhom has clinched โฌ63 million ($70 million) in a Series A raise to advance its lead monoclonal antibody program through a first-in-human trial set to โฆJan Poth https://lnkd.in/eeh8An7y
SciRhom secures โฌ63M Series A for autoimmune disease program
https://endpts.com
To view or add a comment, sign in
-
๐๐ถ๐น๐น๐ ๐ฑ๐ถ๐๐ฐ๐น๐ผ๐๐ฒ๐ ๐ถ๐๐ ๐ณ๐ถ๐ฟ๐๐ ๐ฏ๐ถ๐ผ๐๐ฒ๐ฐ๐ต ๐ฎ๐ฐ๐พ๐๐ถ๐๐ถ๐๐ถ๐ผ๐ป ๐ผ๐ณ ๐๐ต๐ฒ ๐๐ฒ๐ฎ๐ฟ, ๐ฏ๐๐๐ถ๐ป๐ด ๐ ๐ผ๐ฟ๐ฝ๐ต๐ถ๐ฐ ๐ณ๐ผ๐ฟ $๐ฏ.๐ฎ๐ Eli Lilly and Company said Monday it plans to pay $3.2 billion in cash for Morphic Therapeutic, a biotech working on oral integrin. Praveen Tipirneni https://lnkd.in/dfb-NQVt acquisition-of-the-year-buying-morphic-for-3-2b/
Lilly discloses its first biotech acquisition of the year, buying Morphic for $3.2B
https://endpts.com
To view or add a comment, sign in
-
๐๐ฑ๐ฒ๐ฎ๐๐ฎ ๐๐ต๐ผ๐๐ฐ๐ฎ๐๐ฒ๐ ๐ฝ๐ฟ๐ผ๐ผ๐ณ-๐ผ๐ณ-๐ฐ๐ผ๐ป๐ฐ๐ฒ๐ฝ๐ ๐ฑ๐ฎ๐๐ฎ ๐ถ๐ป ๐ฎ ๐ฏ๐ผ๐ผ๐๐ ๐๐ผ ๐๐๐ป๐๐ต๐ฒ๐๐ถ๐ฐ ๐น๐ฒ๐๐ต๐ฎ๐น๐ถ๐๐ ๐ฝ๐น๐ฎ๐ Fresh Phase 2 data are adding weight to Ideaya IDEAYA Biosciences case for a targeted therapy it believes could be a first-in-class treatment option for certain โฆYujiro S. H. https://lnkd.in/d-wViywi
Ideaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397
https://endpts.com
To view or add a comment, sign in
-
๐๐ถ๐ฟ๐ฐ๐น๐ฒ ๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ ๐ฟ๐ฎ๐ถ๐๐ฒ๐ $๐ฑ๐ฐ๐ ๐ฎ๐ ๐ฝ๐ฎ๐ฟ๐ ๐ผ๐ณ ๐ฆ๐ฒ๐ฟ๐ถ๐ฒ๐ ๐ ๐๐ต๐ถ๐น๐ฒ ๐บ๐ฎ๐ฐ๐ฟ๐ผ๐ฐ๐๐ฐ๐น๐ฒ๐ ๐ต๐ฒ๐ฎ๐ ๐๐ฝ Circle Pharma, Inc. a startup working on macrocycles for the โundruggable,โ is seeking about $117 million for a Series D. The company recently closed the first โฆDavid J. Earp, JD, PhD https://lnkd.in/dBk_adUB
Circle Pharma raises $54M as part of Series D while macrocycles heat up
https://endpts.com
To view or add a comment, sign in
-
๐ฆ๐ฒ๐ป๐ถ๐ผ๐ฟ ๐ง๐ฎ๐น๐ฒ๐ป๐ ๐ฆ๐ต๐ถ๐ณ๐ ๐ค๐ฎ ๐ฎ๐ฌ๐ฎ๐ฐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐ In Q2 2024, there have been notable senior-level changes across the Real World Evidence, Digital Health, Consulting, and CDMO sectors. These shifts reflect the industry's ongoing evolution and the increasing demand for leaders with expertise in business transformation, strategic change, and entrepreneurial drive. In the Real World Evidence sector, new senior leaders have been appointed to spearhead efforts in leveraging real-world data for enhanced clinical and commercial insights. These changes aim to strengthen capabilities in generating robust evidence to support regulatory submissions and market access strategies in a highly competitive field, marked by fierce competition from both large corporations and smaller enterprises. ๐จ๐ฆ๐ Kyle Armbrester - CEO at Datavant Brett Kleger - CEO at Inspire Rachael Thomas Higgins - CCO at PicnicHealth Jade Cusick - CCO at Ontada Ben Stormer - CCO at Annexus Health Ryan Sloan - CGO at Galileo Jennifer M. - CGO at Lightship Lindsay Daniel - CHRO at YPrime Joshua Max Davis - SVP Commercial Operations at Ada Health Amy Eaves - BU Head Healthcare & Life Sciences at Synoptek ๐๐๐ฟ๐ผ๐ฝ๐ฒ Marc Funk - CEO at MARBIO Abdelaziz Toumi, PhD, MBA - CEO at Lupin Jonathan Burr - CCO at Cytel Martin Keil - VP & GM at Revvity Roberto Ascione - President at EVERSANA Pamela V. - VP HEOR, Value & Evidence at EVERSANA Jean-Christophe Massot - VP Information & Communications ProductLife Group Frรฉdรฉric GAUSSENS - VP Europe & APAC PharmaLex We are excited to see how Q3 unfolds with any future senior talent shifts. If you are seeking senior-level opportunities or looking to attract senior talent, please contact our executive search team at Luminary Group. Stay tuned for the next series! #realworldevidence #rwe #rwd #regulatoryaffairs #cdmo #pharmaceutical #biotechnology
To view or add a comment, sign in